On Dec. 21, 2020, Aimmune Therapeutics announced that the European Commission (EC) had approved PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy.

PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older. Palforzia should be used in conjunction with a peanut-avoidant diet.

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.